Article
MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma.
Theranostics - 1 Jan 2020
Molloy Abigail R, Najac Chloé, Viswanath Pavithra, Lakhani Aliya, Subramani Elavarasan, Batsios Georgios, Radoul Marina, Gillespie Anne Marie, Pieper Russell O, Ronen Sabrina M
Abstract excerpt
Mutations in isocitrate dehydrogenase 1 (IDH1mut) are reported in 70-90% of low-grade gliomas and secondary glioblastomas. IDH1mut catalyzes the reduction of α-ketoglutarate (α-KG) to 2-hydroxyglutarate (2-HG), an oncometabolite which drives tumorigenesis. Inhibition of IDH1mut is therefore an emerging therapeutic approach, and inhibitors such as AG-120 and AG-881 have shown promising results in phase 1 and 2...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.